Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 8:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Idiopathic Thrombocytopenic Purpura (ITP) Clear all
Not listed Phase 1 Interventional

Post IVIG Medication in Children With Immune Thrombocytopenia

NCT04741139
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Acetaminophen and Diphenhydramine Only Product
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 9, 2026, 8:07 AM EDT
Completed No phase listed Observational

A Real World Study of Treatment Patterns and Effectiveness of Standard of Care in Primary Immune Thrombocytopenia Patients

NCT07805408
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 9, 2026, 8:07 AM EDT
Completed No phase listed Observational

An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers

NCT00005570
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic, Immune Thrombocytopenic Purpura
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 9, 2026, 8:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus for Autoimmune Disease of Blood Cells

NCT00392951
View directory record Official record
Conditions
Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome, Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune, Autoimmune Neutropenia, Lupus Erythematosus, Systemic, Inflammatory Bowel Disease, Rheumatoid Arthritis
Interventions
sirolimus
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 9, 2026, 8:07 AM EDT
Recruiting Phase 1 Interventional

OM336 in Autoimmune Cytopenias

NCT07083960
View directory record Official record
Conditions
AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia
Interventions
OM336
Drug
Lead sponsor
Lakefront Biotherapeutics West LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Duarte, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 9, 2026, 8:07 AM EDT
Recruiting Phase 2 Interventional

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

NCT07104565
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
INCA000585
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Glendale, Arizona • Los Angeles, California • Lone Tree, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 9, 2026, 8:07 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

NCT03275740
View directory record Official record
Conditions
Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 9, 2026, 8:07 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

NCT07007962
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
rilzabrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
Clovis, California • Los Angeles, California • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 9, 2026, 8:07 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura

NCT00002250
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura ( ITP ), HIV Infections
Interventions
CD4-IgG
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 9, 2026, 8:07 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

NCT06721013
View directory record Official record
Conditions
Immune Thrombocytopenia (ITP)
Interventions
Pirtobrutinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 9, 2026, 8:07 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

NCT04278924
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Placebo, TAK-079
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Gainesville, Florida • Peoria, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 9, 2026, 8:07 AM EDT
Completed Phase 2 Interventional Results available

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00441090
View directory record Official record
Conditions
Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
Interventions
Placebo, Avatrombopag tablets
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Anaheim, California • Bakersfield, California • Concord, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 9, 2026, 8:07 AM EDT
Recruiting Phase 1 Interventional

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

NCT04323748
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
rituxan
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Year to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Vahalla, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 9, 2026, 8:07 AM EDT
Withdrawn Not applicable Interventional

Single Incision Versus Standard Laparoscopic Splenectomy

NCT01276561
View directory record Official record
Conditions
Hereditary Spherocytosis, Idiopathic Thrombocytopenic Purpura
Interventions
Single Incision Splenectomy, Laparoscopic Splenectomy
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Year to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 9, 2026, 8:07 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

NCT05653219
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Ianalumab, Eltrombopag, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Yuma, Arizona • Aurora, Colorado • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 9, 2026, 8:07 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

NCT07421167
View directory record Official record
Conditions
Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
Interventions
ianalumab, thrombopoietin receptor agonist (TPO-RA)
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
16
States / cities
Fayetteville, Arkansas • New Haven, Connecticut • Stamford, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 9, 2026, 8:07 AM EDT
Completed Phase 1 Interventional

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

NCT03275454
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
BIVV009 6.5 grams, BIVV009 7.5 grams
Drug
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Georgetown, District of Columbia • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 9, 2026, 8:07 AM EDT
Completed Phase 1 Interventional

Treatment of Autoimmune Thrombocytopenia (AITP)

NCT00001630
View directory record Official record
Conditions
Autoimmune Disease, Autoimmune Hemolytic Anemia, Thrombocytopenia
Interventions
Isolex 300i
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 9, 2026, 8:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects

NCT01289509
View directory record Official record
Conditions
Idiopathic Thrombocytopenia Purpura
Interventions
E5501, Drug: E5501
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 9, 2026, 8:07 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

NCT05653349
View directory record Official record
Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
Ianalumab, Placebo, Corticosteroids
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Yuma, Arizona • Clovis, California • Fountain Valley, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 9, 2026, 8:07 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

NCT01444417
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenic Purpura, Immune Thrombocytopenia
Interventions
Romiplostim, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
1 Year to 17 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
25
States / cities
Orange, California • San Diego, California • Washington D.C., District of Columbia + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 9, 2026, 8:07 AM EDT
Completed Phase 2 Interventional

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

NCT00718692
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Sym001
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Omaha, Nebraska • Philadelphia, Pennsylvania • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 9, 2026, 8:07 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Comparative Autoantibody and Immunologic Cell Marker Study

NCT02422875
View directory record Official record
Conditions
Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 9, 2026, 8:07 AM EDT
Completed No phase listed Observational

Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics

NCT01727999
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 9, 2026, 8:07 AM EDT